MMP9 and breast carcinoma: Gan et al. also designed two novel dihydrotriazine-chalcone compounds (60) previously found to exert antiproliferative effects through dual targeting of dihydrofolate reductase (DHFR) and TrxR, which could inhibit the in vitro migration of MDA-MB-231 breast carcinoma cells through dose-dependent downregulation of matrix metalloproteinase-9 (MMP-9) expression and secretion [159].